MX2023006203A - Vacunas novedosas contra el virus de zika. - Google Patents

Vacunas novedosas contra el virus de zika.

Info

Publication number
MX2023006203A
MX2023006203A MX2023006203A MX2023006203A MX2023006203A MX 2023006203 A MX2023006203 A MX 2023006203A MX 2023006203 A MX2023006203 A MX 2023006203A MX 2023006203 A MX2023006203 A MX 2023006203A MX 2023006203 A MX2023006203 A MX 2023006203A
Authority
MX
Mexico
Prior art keywords
mammal
zika
zika virus
immune response
dna plasmid
Prior art date
Application number
MX2023006203A
Other languages
English (en)
Inventor
Karuppiah Muthumani
David Weiner
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2023006203A publication Critical patent/MX2023006203A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un aspecto de la presente invención se refiere a construcciones de ácido nucleico capaces de expresar un antígeno de Zika que provoca una respuesta inmunitaria en un mamífero contra el virus de Zika, y métodos de usos de estas. Además, hay vacunas de plásmidos de ADN capaces de generar una respuesta inmunitaria contra un virus de Zika en un mamífero, que comprenden un plásmido de ADN y un excipiente farmacéuticamente aceptable y métodos de uso de estas. El plásmido de ADN es capaz de expresar un antígeno de Zika en una célula del mamífero en una cantidad efectiva para provocar una respuesta inmunitaria en el mamífero que tenga reactividad cruzada frente a todas las cepas de Zika.
MX2023006203A 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika. MX2023006203A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US201762462249P 2017-02-22 2017-02-22

Publications (1)

Publication Number Publication Date
MX2023006203A true MX2023006203A (es) 2023-06-12

Family

ID=59685658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010291A MX2018010291A (es) 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika.
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018010291A MX2018010291A (es) 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika.

Country Status (10)

Country Link
US (2) US11648303B2 (es)
EP (1) EP3419660A4 (es)
JP (2) JP7012365B2 (es)
KR (1) KR20190003471A (es)
CN (2) CN109152826B (es)
AU (2) AU2017222644B2 (es)
BR (1) BR112018017307A2 (es)
CA (1) CA3015792A1 (es)
MX (2) MX2018010291A (es)
WO (1) WO2017147458A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3419660A4 (en) * 2016-02-25 2019-11-06 The Trustees Of The University Of Pennsylvania NEW VACCINES AGAINST ZIKA VIRUS
CA3040123A1 (en) * 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
CN111615397A (zh) 2017-11-03 2020-09-01 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CN111601885A (zh) 2017-11-30 2020-08-28 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
EP3826672A4 (en) * 2018-07-23 2022-04-20 The University of Adelaide VACCINE AGAINST THE ZIKA VIRUS
US20220017605A1 (en) * 2018-10-31 2022-01-20 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
WO2022169339A1 (ko) * 2021-02-05 2022-08-11 에스티팜 주식회사 신규 핵산 분자

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774045B2 (en) * 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
EP2026839A4 (en) 2005-12-14 2009-04-01 Univ Oklahoma RNA VIRUS VACCINE AND METHODS
EP2234624B1 (en) 2008-01-11 2018-06-20 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
BRPI0921359A2 (pt) 2008-11-17 2015-08-25 Inovio Pharmaceuticals Inc Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos
KR20120093163A (ko) * 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
CA2777705C (en) * 2009-11-02 2019-03-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8691961B1 (en) 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
EP2550292B1 (en) 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
CN105821078A (zh) * 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
US9243041B2 (en) * 2011-01-31 2016-01-26 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
CN104114697A (zh) 2011-12-09 2014-10-22 巴斯德研究所 多重免疫筛选分析
AU2014228497B2 (en) 2013-03-15 2017-03-02 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
CN108601825B (zh) * 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 疫苗组合物
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017140905A1 (en) * 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
EP3419660A4 (en) * 2016-02-25 2019-11-06 The Trustees Of The University Of Pennsylvania NEW VACCINES AGAINST ZIKA VIRUS
US11241490B2 (en) * 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus

Also Published As

Publication number Publication date
AU2021258056A1 (en) 2021-11-25
EP3419660A4 (en) 2019-11-06
MX2018010291A (es) 2019-06-06
US20210315987A1 (en) 2021-10-14
AU2017222644B2 (en) 2021-07-29
JP2019506175A (ja) 2019-03-07
WO2017147458A1 (en) 2017-08-31
KR20190003471A (ko) 2019-01-09
CN109152826A (zh) 2019-01-04
AU2017222644A1 (en) 2018-09-13
BR112018017307A2 (pt) 2019-01-08
JP7012365B2 (ja) 2022-03-04
EP3419660A1 (en) 2019-01-02
CN115927399A (zh) 2023-04-07
AU2021258056B2 (en) 2024-04-04
US20240115689A1 (en) 2024-04-11
CA3015792A1 (en) 2017-08-31
CN109152826B (zh) 2022-11-04
US11648303B2 (en) 2023-05-16
JP2022023241A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
IN2015DN02546A (es)
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
WO2014004385A3 (en) Anti-cancer vaccines
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
MX2022003664A (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
AR110730A1 (es) Vacunas de cepas recombinantes de listeria y método para usarlas en inmunoterapia de cáncer
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
WO2017123976A8 (en) Methods and compositions for influenza vaccination
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
WO2017059177A3 (en) Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages